Sun Pharma presents key dermatology data at EADV Congress in Amsterdam EP News Bureau Sep 27, 2024 Sun Pharmaceutical Industries announces presentations on deuruxolitinib and tildrakizumab at the 33rd European Academy of…
US FDA accepts Sun Pharma’s NDA for Deuruxolitinib EP News Bureau Oct 6, 2023 Deuruxolitinib is being evaluated for treatment of moderate to severe alopecia areata
US FDA asks Sun Pharma to stop trial on dermatological drug citing potential of blood clots EP News Bureau May 2, 2023 Sun Pharma acquired deuruxolitinib when it bought Concert Pharmaceuticals for $576 million earlier this year
